926 related articles for article (PubMed ID: 28807335)
21. Grading of neuroendocrine neoplasms: mitoses and Ki-67 are both essential.
van Velthuysen ML; Groen EJ; van der Noort V; van de Pol A; Tesselaar ME; Korse CM
Neuroendocrinology; 2014; 100(2-3):221-7. PubMed ID: 25358267
[TBL] [Abstract][Full Text] [Related]
22. Neuroendocrine tumors involving the gastroenteropancreatic tract: a clinicopathological evaluation of 773 cases.
Estrozi B; Bacchi CE
Clinics (Sao Paulo); 2011; 66(10):1671-5. PubMed ID: 22012036
[TBL] [Abstract][Full Text] [Related]
23. [Chinese expert consensus on gastroenteropancreatic neuroendocrine neoplasms (2022 edition)].
Expert Committee on Neuroendocrine Neoplasms, Chinese Society of Clinical Oncology
Zhonghua Zhong Liu Za Zhi; 2022 Dec; 44(12):1305-1329. PubMed ID: 36575783
[TBL] [Abstract][Full Text] [Related]
24. Diagnostic and therapeutic role of endoscopy in gastroenteropancreatic neuroendocrine neoplasms.
Attili F; Capurso G; Vanella G; Fuccio L; Delle Fave G; Costamagna G; Larghi A
Dig Liver Dis; 2014 Jan; 46(1):9-17. PubMed ID: 23731843
[TBL] [Abstract][Full Text] [Related]
25. Grade Assignment by Ki-67 Proliferative Index, Mitotic Count, and Phosphohistone H3 Count in Surgically Resected Gastrointestinal and Pancreatic Neuroendocrine Tumors.
Murphy CE; McCormick KA; Shankaran V; Reddi DM; Swanson PE; Upton MP; Papanicolau-Sengos A; Khor S; Westerhoff M
Pancreas; 2017; 46(10):1359-1365. PubMed ID: 29040195
[TBL] [Abstract][Full Text] [Related]
26. Grading lung neuroendocrine tumors: Controversies in search of a solution.
Pelosi G; Pattini L; Morana G; Fabbri A; Faccinetto A; Fazio N; Valeri B; Sonzogni A
Histol Histopathol; 2017 Mar; 32(3):223-241. PubMed ID: 27628949
[TBL] [Abstract][Full Text] [Related]
27. Re-evaluation of cases with gastroenteropancreatic neuroendocrine tumors between 2004 and 2012 according to the 2010 criteria.
Ozkara S; Aker F; Yesil A; Senates E; Canbey C; Yitik A; Gonen C
Hepatogastroenterology; 2013 Oct; 60(127):1665-72. PubMed ID: 24627925
[TBL] [Abstract][Full Text] [Related]
28. Treatment of Gastroenteropancreatic Neuroendocrine Tumors.
Perez K; Chan J
Surg Pathol Clin; 2019 Dec; 12(4):1045-1053. PubMed ID: 31672293
[TBL] [Abstract][Full Text] [Related]
29. Gastroenteropancreatic neuroendocrine neoplasms: selected pathology review and molecular updates.
Chai SM; Brown IS; Kumarasinghe MP
Histopathology; 2018 Jan; 72(1):153-167. PubMed ID: 29239038
[TBL] [Abstract][Full Text] [Related]
30. [Grading of neuroendocrine tumors].
Saeger W; Schnabel PA; Komminoth P
Pathologe; 2016 Jul; 37(4):304-13. PubMed ID: 27379621
[TBL] [Abstract][Full Text] [Related]
31. Reassessing the grade of gastroenteropancreatic neuroendocrine neoplasms.
Klimstra DS
Endocrine; 2016 Jul; 53(1):4-6. PubMed ID: 27150611
[No Abstract] [Full Text] [Related]
32. G3 GEP NENs category: are basic and clinical investigations well integrated?
Milione M; Fazio N
Endocrine; 2018 Apr; 60(1):28-30. PubMed ID: 28733935
[TBL] [Abstract][Full Text] [Related]
33. Are G3 ENETS neuroendocrine neoplasms heterogeneous?
Vélayoudom-Céphise FL; Duvillard P; Foucan L; Hadoux J; Chougnet CN; Leboulleux S; Malka D; Guigay J; Goere D; Debaere T; Caramella C; Schlumberger M; Planchard D; Elias D; Ducreux M; Scoazec JY; Baudin E
Endocr Relat Cancer; 2013 Oct; 20(5):649-57. PubMed ID: 23845449
[TBL] [Abstract][Full Text] [Related]
34. Evaluation of an Image-based Automated Detection System in Detecting Ki67 Proliferation Index and Correlation with the Traditional Eye-Ball Method in Gastroenteropancreatic Neuroendocrine Tumors.
Dere Y; Ozkaraca O; Cetin G; Dere O
J Coll Physicians Surg Pak; 2019 Feb; 29(2):137-140. PubMed ID: 30700352
[TBL] [Abstract][Full Text] [Related]
35. Pathologic Considerations in Gastroenteropancreatic Neuroendocrine Tumors.
Bellizzi AM
Surg Oncol Clin N Am; 2020 Apr; 29(2):185-208. PubMed ID: 32151355
[TBL] [Abstract][Full Text] [Related]
36. [Gastroenteropancreatic neuroendocrine/endocrine tumors. Current pathologic-diagnostic view].
Schmitt-Gräff A; Nitschke R; Wiedenmann B
Pathologe; 2001 Mar; 22(2):105-13. PubMed ID: 11321726
[TBL] [Abstract][Full Text] [Related]
37. Clinicopathological features and outcome of type 3 gastric neuroendocrine tumours.
Min BH; Hong M; Lee JH; Rhee PL; Sohn TS; Kim S; Kim KM; Kim JJ
Br J Surg; 2018 Oct; 105(11):1480-1486. PubMed ID: 29893418
[TBL] [Abstract][Full Text] [Related]
38. Two cases of lung neuroendocrine carcinoma with carcinoid morphology.
Inafuku K; Yokose T; Ito H; Eriguchi D; Samejima J; Nagashima T; Nakayama H; Suzuki M; Yamada K; Masuda M
Diagn Pathol; 2019 Sep; 14(1):104. PubMed ID: 31511024
[TBL] [Abstract][Full Text] [Related]
39. Primary Site Predicts Grade for Gastroenteropancreatic Neuroendocrine Tumors.
Fitzgerald TL; Mosquera C; Lea CS; McMullen M
Am Surg; 2017 Jul; 83(7):799-803. PubMed ID: 28738955
[TBL] [Abstract][Full Text] [Related]
40. Grade Increases in Gastroenteropancreatic Neuroendocrine Tumor Metastases Compared to the Primary Tumor.
Grillo F; Albertelli M; Brisigotti MP; Borra T; Boschetti M; Fiocca R; Ferone D; Mastracci L
Neuroendocrinology; 2016; 103(5):452-9. PubMed ID: 26337010
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
